clinical trial · NCT04943900
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb·phase1·completed·n = 67
Advanced Solid TumorsBMS-986416Nivolumab
brief summary
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
started
Aug 9, 2021
primary completion
Feb 27, 2025
completion
Feb 27, 2025
last updated
Apr 9, 2025
official title
A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol